Table 13.

Features of the antibody-drug conjugates approved by the Food and Drug Administration (FDA) from 2011 to 2021. The order of drugs is tabulated in order of most recent to oldest registration date.

No.	Generic Name of Drug	Brand Name and Company	First FDA/EMA Approved Date	Structure	Molecular Target	Route of Administration	Indication	Adverse Effects	Reference
1	Belantamab mafodotin-blmf	BLENREP GlaxoSmithKline, Brentford, England	FDA: 5 August 2020 EMA: 25 August 2020		BCMA 1	Intravenous	Multiple Myeloma	Ocular toxicity, thrombocytopenia, infusion-related reactions, gastrointestinal disorders, pyrexia, fatigue	[265,266]
2	Polatuzumab vedotin-piiq	POLIVY Genentech, Inc., South San Francisco, CA, USA	FDA: 10 June 2019 EMA: 16 January 2020		CD79b 2	Intravenous	Diffuse Large B-Cell Lymphoma	Cytopenias	[262,267,268]
3	Inotuzumab ozogamicin	BESPONSA Pfizer Inc., New York, NY, USA	FDA: 17 August 2017 EMA: 29 June 2017		CD22 3	Intravenous	Acute Lymphoblastic Leukemia	Cytopenias (including febrile neutropenia), infections, nausea, pyrexia, abnormal liver function and venoocclusive liver disease	[269,270]
4	Brentuximab vedotin	ADCETRIS Seattle Genetics, Inc., Bothell, WA, USA	FDA: 19 August 2011 EMA: 25 October 2012		CD30 4	Intravenous	Lymphoma, Hodgkin’s Lymphoma, Mycosis Fungoides	Neutropenia, anemia, peripheral sensory neuropathy, nausea, fatigue, constipation, diarrhea, vomiting, and pyrexia	[260,271,272]

¹ BCMA: B-cell maturation antigen. ² CD79b: cluster of differentiation 79b. ³ CD22: cluster of differentiation 22. ⁴ CD30: cluster of differentiation 30.